Form 4: Astria Therapeutics Director Granted 26,550 Stock Options

Astria Therapeutics, Inc. director Anthony Gregg Lapointe was granted 26,550 stock options with an exercise price of $5.79, vesting over one year.

Summary

• Anthony Gregg Lapointe, a Director of Astria Therapeutics, Inc. (ATXS), was granted 26,550 stock options on June 11, 2025.
• The options have an exercise price of $5.79 per share.
• These options will vest in their entirety on the one-year anniversary of the grant date, specifically June 11, 2026, contingent on the director's continued service.
• The expiration date for these stock options is June 10, 2035.
• Following this transaction, Mr. Lapointe beneficially owns 26,550 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates standard corporate governance practices for director compensation, aligning interests with shareholders. It is not a major market-moving event but reflects ongoing operational norms.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• The options have a long expiration date (June 10, 2035), providing a significant window for potential value realization.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to attract and retain talent and align their financial interests with company performance.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule (one-year cliff vesting) is a common approach for director equity grants, ensuring continued service and alignment.

Related Party Transactions

• Anthony Gregg Lapointe, a director of Astria Therapeutics, Inc., was granted 26,550 stock options by the company, which constitutes a transaction with a related party as part of his compensation.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's financial incentives with the company's long-term stock performance, potentially benefiting shareholders if the stock price increases.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest on June 11, 2026, subject to the director's continued service.

Key Dates

Keywords

Astria Therapeutics, ATXS, Stock Option, Director Compensation, Insider Transaction, Form 4, Beneficial Ownership, Equity Grant